In Conversation with Matt Dolan

As a senior research analyst focused on medical technology: (devices and diagnostics) with ROTH Capital Partners, Matt Dolan’s investment views have been cited by a “Who’s Who” of publications on Wall Street. Prior to joining Roth in 2003, Mr. Dolan, a graduate of Northwestern University, formed a trading group at the Chicago Board of Trade [...]

D. Medical CEO interviewed on Bloomberg TV

Efri Argaman, CEO of D. Medical Industries (NASDAQ, TASE:DMED), was interviewed today by Sara Eisen on Bloomberg Television’s “InsideTrack.” Mr. Argaman discussed a host of topics, ranging from the state of the U.S. diabetes market, regulatory oversight and D. Medical’s sales strategy in the U.S. Instead of setting up a direct and costly U.S. sales [...]

Cipher achieves sales milestone for Lipofen

Cipher Pharmaceuticals (TSX:DND) has reached a sales milestone for Lipofen, its fenofibrate product, triggering a $1 million payment from Kowa Pharmaceuticals America, the company’s U.S. marketing and distribution partner. The one-time milestone, which is based on sales performance over a trailing 12-month period, reflects a steady increase in new prescriptions during the past quarter. Cipher’s [...]

enGene initiates $20 million financing to advance lead product

Closely held enGene of Vancouver is working on a financing of up to $20 million with venture capital funds to conduct the first two phases of human clinical trials of its intestinal immunotherapy platform to treat ulcerative colitis, a major subtype of Inflammatory Bowel Disease (IBD). “We have built significant momentum for the financing in [...]

Health Canada accepts Cipher acne filing for review

Health Canada has accepted for review a New Drug Submission by Cipher Pharmaceuticals (TSX: DND) for its CIP-Isotretinoin, a novel, patented formulation of the acne medication isotretinoin. The company expects a response from Health Canada in the first quarter of 2013. “Health Canada’s acceptance moves us a step closer to the commercialization of CIP-Isotretinoin in [...]

Roth upgrades Spectrum to buy

Roth Capital Partners has upgraded Spectrum Pharmaceuticals (NASDAQ:SPPI) to “buy” from “neutral” and raised its 12-month price target to $20 from $11, citing an increasing focus on revenue and data catalysts in 2012. The stock was quoted at $13.93 Thursday afternoon. “We base our upgrade on our belief that Fusilev revenue will remain strong at [...]

Roth starts Intellipharmaceutics at buy

Roth Capital Partners has initiated coverage of Intellipharmaceutics (NASDAQ:IPCI; TSX:I) with a “buy” rating and 12-month price target of $5.25, saying the emerging generics company could launch four new products in the coming 12-to-18 months. “We believe that this momentum could unlock value for this under covered stock,” writes analyst Scott Henry. The stock closed [...]

enGene establishes clinical advisory board

Closely held enGene has established a clinical advisory board of preeminent clinical investigators in the field of Inflammatory Bowel Disease (IBD) to provide the company with guidance on the regulatory pathway and clinical development of its EG-10 candidate for the treatment of ulcerative colitis. The newly appointed clinical advisors are Drs. Brian Feagan, Geert D’Haens [...]

TearLab Osmolarity System gets CLIA Waiver from FDA

The FDA has granted a waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity System. The FDA took the action after reviewing and accepting labeling submitted to it by TearLab. “We believe that, with CLIA Waiver and Medicare reimbursement in place, and with the updated American Academy [...]

Alitair builds value without outside investors

Dr. William W. Howard likes to say there’s a lesson to be learned in how closely held Alitair Pharmaceuticals has spent the first couple years of its existence developing a portfolio of respiratory therapeutics and a drug safety technology: make some money first and then go out and get investors. “We’ve been able to develop [...]

Next Page »